NCT07161700Phase 2Enrolling by invitation

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Study sponsor: Seaport Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05Estimated
Enrollment · participants360Estimated
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview